Combination of Non-Cytotoxic Suramin With Docetaxel and Carboplatin in Chemo-Naive NSCLC: A Randomized Single-Blind Placebo-Controlled Phase II Study
Phase of Trial: Phase II
Latest Information Update: 28 May 2015
At a glance
- Drugs Suramin sodium (Primary) ; Carboplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 18 Nov 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Sep 2010 Additional location [USA] identified and lead trial investigator as reported by ClinicalTrials.gov.